Skip to main content

Uncontrolled Hypertension Unchanged in US Adults

HYATTSVILLE, MD — Only about 48% of adults with hypertension had it under control during 2015–2016, according to data released today by the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC)[1].
"This finding that just under half of adults with hypertension have their BP under control is consistent with estimates since 2010," first author Cheryl Fryar, NCHS Division of Health and Nutrition Examination Surveys, told theheart.org | Medscape Cardiology. "However, this statistic shows that we have yet to meet the Healthy People 2020 goal of 61.2% for hypertension control."
The report also shows that hypertension is more prevalent in US non-Hispanic black adults than in other race/ethnic-origin groups.
Hypertension raises the risk of cardiovascular disease and "remains an important public-health challenge" in the US. Effective control of elevated blood pressure has been shown to reduce stroke, MI, and heart failure, Fryar and her colleagues note.
Based on National Health and Nutrition Examination Survey (NHANES) data, in 2015–2016, the overall prevalence of hypertension among adults was 29.0%. It was similar in men (30.2%) and women (27.7%) and increased with age, from 7.5% in adults 18 to 39, to 33.2% in adults 40 to 59 years, to 63.1% in those aged 60 and older.
The prevalence of hypertension was higher in men than women in those aged 18 to 39 (9.2% vs 5.6%) and those 40 to 59 (37.2% vs 29.4%), but in the 60+ age group, men had a lower prevalence of hypertension than women (58.5% vs 66.8%).
There were also differences in hypertension prevalence by race and Hispanic origin during 2015–2016. For all adults, the prevalence of hypertension among non-Hispanic black adults was higher (40.3%) than among non-Hispanic white (27.8%), non-Hispanic Asian (25.0%), and Hispanic (27.8%) adults.
Uncontrolled BP Common
Among adults with hypertension during 2015–2016, only 48.3% had controlled hypertension, the authors say.
The prevalence of controlled hypertension overall increased with age and was lower among those aged 18 to 39 years (32.5%) than among those aged 40 to 59 years (50.8%) and 60 and over (49.4%). A higher percentage of women had controlled hypertension than men, both overall (52.5% vs 45.7%) and among those aged 18 to 39 (62.6% vs 15.5%).
The prevalence of hypertension control among all adults with hypertension was higher among non-Hispanic whites (50.8%) than among non-Hispanic blacks (44.6%) and non-Hispanic Asians (37.4%).
Using NHANES data, the researchers also assessed trends in overall prevalence and control of hypertension between 1999 and 2016.
They found no significant change in the prevalence of hypertension among US adults during the 9-year study period. However, the prevalence of controlled hypertension among adults rose from 31.6% in 1999–2000 to 53.1% in 2009–2010, with no significant changes from 2009–2010 through the end of the study period.
There was a nonsignificant decrease in hypertension control between 2013–2014 and 2015–2016 (53.9% to 48.3%).
REFERENCES:
  • Fryar CD, OstchegaY, Hales CM, et al. National Center for Health Statistics Data Brief 289. Hypertension Prevalence and Control Among Adults: United States, 2015–2016. October 2017. Article

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more